ING Groep NV vs McKesson Corporation — how do they compare? ING Groep NV trades at $33.15 (market cap $93.76B), while McKesson Corporation trades at $930 (market cap $108.46B). The key difference: McKesson Corporation is the larger of the two by market cap, and ING Groep NV pays the higher dividend (3.95%). Which is the better fit depends on your goals — on Pluang, investors hold ING Groep NV for 93 Days and McKesson Corporation for 74 Days on average.
| ING | MCK | |
|---|---|---|
Market Cap | $93.76B | $108.46B |
Volume | 4,620,220 | 712,607 |
Sector | Financials | Health |
52-Week High | $37.27 | $995.69 |
52-Week Low | $23.66 | $725.17 |
Typical Hold Time | 93 Days | 74 Days |
Enterprise Value | $236.48B | $115.00B |
Dividend Yield | 3.95% | 0.4% |
Signals from Pluang's Aura AI — not financial advice
ING trades at $33.92, down 2.81% on the day, with a bearish technical signal from moving averages and oscillators. The company reported revenue of $22.90 billion in 2025, with net income of $6.33 billion and a net margin of 28.34%. Recent earnings beats and a raised 2027 ROE target above 16% highlight operational strength, though cash flow trends show persistent net outflows.
The outlook is mixed: strong profitability and analyst consensus (64.71% buy ratings) support upside, but bearish technicals and regulatory scrutiny in Australia pose risks. Valuation appears reasonable with a P/E of 13.09, offering a potential entry for long-term investors focused on execution of growth initiatives.
McKesson Corporation (MCK) trades at $910.33, down 1.23% today, but maintains strong analyst support with 80.65% buy ratings and a $956.43 consensus price target. The stock shows bullish technical momentum with recent earnings beats and a major distribution agreement extension with CVS Health through 2032. Revenue growth has accelerated from $264B in 2022 to $359B in 2025, though net margins remain thin at 1.12%.
MCK presents a compelling growth story with consistent earnings outperformance and strategic partnerships driving long-term visibility. However, investors face risks from margin compression, drug pricing pressures, and high leverage with negative shareholder equity. The current valuation at 24.42x P/E appears reasonable given the company's market leadership and oncology growth prospects.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →